Skip to main content

Table 1 Characteristics of subjects

From: Disturbed microcirculation in the hands of patients with systemic sclerosis detected by fluorescence optical imaging: a pilot study

Subjects’ characteristics Systemic sclerosis (SSc) Limited (cutaneous) SSc Diffuse cutaneous SSc Healthy cohort
n = 63 n = 40 n = 23 n = 26
Female: n (%) 52 (82.5%) 35 (87.5%) 17 (73.9%) 19 (73.1%)
Mean age in years (±SD) 56.4 (±14.4) 56.4 (±14.9) 56.6 (±13.4) 28.8 (±9.6)
Mean disease duration (in years ± SD) since
 First Raynaud’s 13.3 (±12.8) 14.6 (±12.3) 11.1 (±13.6) Not present
 First non-Raynaud’s symptoms 9.8 (±9.4) 9.7 (±9.6) 9.8 (±9.3) Not present
Patients with Raynaud’s in the past week
 Number of patients (%) 57 (90.4%) 36 (90.0%) 21 (91.3%) Not present
 Mean number of episodes (±SD) 15.5 (±22.4) 17.5 (±27.3) 11.9 (±8.8)
 Mean impact on day-to-day life using VAS 0-100 (±SD) 36.3 (±29.6) 37.0 (±29.7) 35.1 (±30.1)
Digital ulcers/pitting scars, n (%) 37 (58.7%) 18 (45.0%) 19 (82.6%) Not present
Skin involvement
 Mean mRSS ± SD 9.0 (±8.2) 4.6 (±3.5) 16.5 (±8.6) Not present
Organ involvement, n (%)
 Lung 23 (36.5%) 9 (22.5%) 14 (60.9%) Not present
 Gastrointestinal 42 (66.7%) 25 (62.5%) 17 (73.9%)
 Heart 10 (15.9%) 3 (7.5%) 7 (30.4%)
Capillaroscopy pattern, n (%) [21]
 Early 11 (17.5%) 9 (22.5%) 2 (8.7%)  
 Active 25 (39.7%) 18 (45.0%) 7 (30.4%)
 Late 24 (38.1%) 11 (27.5%) 13 (56.5%)
 Non-SSc 1 (1.6%) 1 (2.5%) 0
 Not done 2 (3.2%) 1 (2.5%) 1 (4.3%) 26 (100%)
Current medication, n (%)
 Iloprost 38 (60.3%) 27 (67.5%) 11 (47.8%) 0
 Oral vasodilating drugsa 42 (66.7%) 25 (62.5%) 17 (73.9%) 0
  1. One patient with limited systemic sclerosis (SSc sine scleroderma) was included in the limited cutaneous SSc subgroup
  2. VAS visual analogue scale, mRSS modified Rodnan skin score
  3. aCalcium channel blockers, AT1 receptor antagonists, ACE inhibitors, endothelin receptor antagonists, PDE-5 inhibitors; alpha receptor antagonists